MYLAN-VERAPAMIL SR TABLET (EXTENDED-RELEASE)

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

VERAPAMIL HYDROCHLORIDE

Доступна з:

MYLAN PHARMACEUTICALS ULC

Код атс:

C08DA01

ІПН (Міжнародна Ім'я):

VERAPAMIL

Дозування:

120MG

Фармацевтична форма:

TABLET (EXTENDED-RELEASE)

Склад:

VERAPAMIL HYDROCHLORIDE 120MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

100

Тип рецепту:

Prescription

Терапевтична области:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

Огляд продуктів:

Active ingredient group (AIG) number: 0113846001; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2016-01-08

Характеристики продукта

1
PRODUCT MONOGRAPH
PR
MYLAN-VERAPAMIL
SR
verapamil hydrochloride sustained-release tablets, USP
120 mg, 180 mg and 240 mg
Antihypertensive Agent
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke ON
M8Z 2S6
Control No: 235062
Date of Revision: January 15, 2020
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................................
3
SUMMARY PRODUCT
INFORMATION………………………………………………..………………3
INDICATIONS AND CLINICAL USE
.......................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
4
WARNINGS AND PRECAUTIONS
...........................................................................................................
5
ADVERSE REACTIONS
...........................................................................................................................
11
DRUG INTERACTIONS
...........................................................................................................................
14
DOSAGE AND ADMINISTRATION
.......................................................................................................
24
OVERDOSAGE
.........................................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
27
STORAGE AND STABILITY
...................................................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
32
PART II: SCIENTIFIC INFORMATION
.....................................................................................................
34
PHARMACEUTICAL INFORMATION
........